Metrion Biosciences is a UK-based Contract Research Organisation (CRO) specialising in high quality ion channel drug discovery services. We are leaders in
Location: United Kingdom, England, Cambridge
Total raised: $9.3M
Investors 2
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| - | Gresham Ho... | greshamhou... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 20.12.2023 | - | $4.68M | - |
| 06.04.2021 | - | $3.8M | Gresham Ho... |
| 28.08.2018 | - | $819.77K | - |
Mentions in press and media 22
| Date | Title | Description |
| 28.04.2025 | Metrion Biosciences launches NaV1.9 high-throughput screening assay to strengthen screening portfolio and advance research on new medicines for pain | Validated drug discovery assay overcomes previous challenges in targeting NaV1.9 ion channels for chronic pain signalling Completes unique suite of rapid, scalable pain-related sodium channel assays and services to accelerate hit-to-lead an... |
| 20.12.2023 | Metrion Biosciences closes £3.7m new equity financing | Cambridge, UK - Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, announces that it has secured £3.5m in new equity financing, including £2.5m from lead investor Maven Capital Partners (Maven)... |
| 20.12.2023 | Metrion Biosciences Raises £3.7M in New Equity Funding | Metrion Biosciences, a Cambridge, UK-based ion channel CRO and drug discovery company, raised £3.7M in funding. The round was led by Maven Capital Partners, alongside Gresham House Ventures. The company intends to use the funds to to furthe... |
| 01.08.2023 | Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Screening Service | Metrion is now a member of the UK GLP (Good Laboratory Practice) Compliance Monitoring Programme New service with GLP certification further strengthens Metrion’s support for small molecule therapeutics development Cambridge, UK, 01 August 2... |
| 06.07.2023 | Metrion Biosciences expands senior leadership team with appointments of Dr Robert Kirby as COO and Dr Edward Stevens as CSO | Dr Stevens promoted from Director of Drug Discovery, and Dr Kirby promoted from Director of Operations Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the app... |
| 30.11.2022 | Metrion Biosciences invests in new High Throughput Screening capability and expanded facilities | Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the launch of its High Throughput Screening (HTS) capability, as well as the expansion of its state-of-the-art... |
| 22.09.2021 | Metrion Biosciences expands into new headquarters to support continued growth | Metrion Biosciences expands into new headquarters to support continued growth 22-09-2021 Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, today announced that the company has moved to lar... |
| 06.04.2021 | Metrion Biosciences Raises £2.75M in Funding | Metrion Biosciences, a Cambridge, UK-based contract research organisation (CRO) catering to the drug discovery market, raised £2.75m in funding. Gresham House Ventures made a £2.25m investment. Gresham House Ventures’ investment is led by M... |
| 06.04.2021 | Metrion Biosciences closes £2.7m new equity financing | Metrion Biosciences closes £2.7m new equity financing 06-04-2021 Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, today announced that it has secured £2.7m in new equity financing, including £2.25m fro... |
| 06.04.2021 | Metrion Biosciences closes £2.7m new equity financing | Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, today announced that it has secured £2.7m in new equity financing, including £2.25m from lead investor Gresham House Ventures. The funding will be used ... |
Show more